In this newly created position, Brandon will lead manufacturing and operations at the company's 183,000 square foot Department of Defense Advanced Development and Manufacturing facility in Alachua, Florida.
Prior to joining Ology Bioservices, Brega served in various positions at Merck and Co., most recently as Associate vice president, Plant Management at the company's Durham, North Carolina location the largest vaccines-only facility in Merck's network.
Prior to joining Merck, Brega worked for a number of animal health manufacturers including Pfizer Inc., Wyeth Pharmaceuticals, Boehringer Ingelheim and Merial Ltd., leading operations and technical organizations in the production of vaccines, biologics and sterile injectables.
He has broad base of experience with both drug substance and drug product manufacturing across both small and large molecules.
Brega holds both a Bachelor of Science in Biology and Master of Arts in Management from Doane University and earned a Masters Certification in Six Sigma and Lean Six Sigma Black Belt from Villanova University.
Ology Bioservices serves both government and commercial clients, specialising in biologic drug substance manufacturing, from early stage through commercial product.
The company has 183,000 square feet of manufacturing, process development and QA/QC space in its Department of Defense Advanced Development and Manufacturing Facility in Florida.
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV